ALOX5 promotes pancreatic cancer invasion and metastasis by driving tumor-associated macrophage M2 polarization via the JAK/STAT pathway, however, the ALOX5 inhibitor zileuton, currently the only approved agent in this class, can suppress these effects [150]; Bin Wang et al. reported that Nordy (dl-nordihydroguaiaretic acid compound), another ALOX5 inhibitor, induces differentiation and inhibits self-renewal in glioma stem-like cells [151]; Clau (Clausenamide) was found to inhibit lipid peroxidation and ferroptosis by blocking ALOX5 phosphorylation and nuclear translocation [152]. Here, ALOX5 is linked to neoplasm.